Interleukin‐2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: A protocol with early elimination of steroids and reduction of tacrolimus dosage
Chi Leung Liu, Sheung Tat Fan, Chung Mau Lo, See Ching Chan, Irene O. Ng, Ching Lung Lai, John Wong – 20 May 2004 – A prospective evaluation was performed to study the potential benefits of the use of interleukin‐2 receptor antibody (IL‐2Rab) in the induction therapy with early elimination of steroid and reduction of tacrolimus dosage in liver transplant recipients among whom 94% had chronic hepatitis B infection.